Clinical trial
Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug…
NCT02475629 · TaiMed Biologics Inc., Industry · Completed
Key facts
| NCT number | NCT02475629 |
|---|---|
| Title | Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV |
| Official title | A Phase 3, Single Arm, 24-Week, Multicenter Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant HIV-1 |
| Lead sponsor | TaiMed Biologics Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV |
| Intervention type | Biological, Drug |
| Interventions | ibalizumab, Optimized Background Regimen (OBR) |
| Enrollment | 40 |
| Start date | Aug 1, 2015 |
| Primary completion | Oct 1, 2016 |
| Completion | Dec 1, 2016 |
| First posted | Jun 19, 2015 |
| Last update posted | Mar 19, 2020 |
| Countries | Puerto Rico, Taiwan, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: